Insulet (PODD) to Release Earnings on Thursday
Insulet (NASDAQ:PODD) will release its earnings after the market closes on Thursday, August 8th. Analysts expect earnings of $0.56 per share for the quarter. Insulet last reported earnings on May 9th, beating analysts' estimates. The company's stock performance has a 52-week low of $125.82 and a high of $281.83. Insulet has been rated as a "Moderate Buy" with a consensus target price of $239.18.
Insulet (NASDAQ:PODD - Get Free Report) is set to announce its earnings results after the market closes on Thursday, August 8th. Analysts expect the company to announce earnings of $0.56 per share for the quarter. Insulet has set its FY 2024 guidance at EPS and its Q2 2024 guidance at EPS.Individual that are interested in registering for the company's earnings conference call can do so using this link.
- Are These 5 Undervalued Stocks Ready to Break Out?
Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings results on Thursday, May 9th. The medical instruments supplier reported $0.73 earnings per share for the quarter, topping analysts' consensus estimates of $0.39 by $0.34. The company had revenue of $441.70 million during the quarter, compared to analysts' expectations of $424.05 million. Insulet had a return on equity of 34.06% and a net margin of 13.14%. The business's quarterly revenue was up 23.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.23 earnings per share. On average, analysts expect Insulet to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.
Insulet Stock Performance
Shares of NASDAQ PODD opened at $194.35 on Thursday. The business's 50-day simple moving average is $193.88 and its 200-day simple moving average is $184.37. The company has a debt-to-equity ratio of 1.72, a quick ratio of 2.75 and a current ratio of 3.74. Insulet has a 52 week low of $125.82 and a 52 week high of $281.83. The firm has a market cap of $13.61 billion, a price-to-earnings ratio of 58.89, a P/E/G ratio of 3.45 and a beta of 1.16.
Analyst Upgrades and Downgrades
- 5 top healthcare stocks for earnings growth in 2024
A number of research firms have recently commented on PODD. Canaccord Genuity Group reissued a "buy" rating and issued a $234.00 price target on shares of Insulet in a research report on Tuesday, July 23rd. Raymond James cut their target price on shares of Insulet from $218.00 to $213.00 and set an "outperform" rating for the company in a research report on Friday, May 10th. Barclays lowered their price target on Insulet from $213.00 to $200.00 and set an "equal weight" rating on the stock in a research report on Monday, May 13th. Wolfe Research raised Insulet from a "peer perform" rating to an "outperform" rating and set a $200.00 price objective for the company in a research report on Tuesday, May 7th. Finally, Redburn Atlantic assumed coverage on Insulet in a research note on Thursday, May 30th. They set a "buy" rating and a $235.00 target price for the company. Four equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $239.18.
Check Out Our Latest Stock Analysis on PODD
Insider Activity
- MarketBeat ‘Stock of the Week’: Intuitive Surgical hits new highs
In other news, Director Timothy J. Scannell sold 7,000 shares of Insulet stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $190.51, for a total transaction of $1,333,570.00. Following the sale, the director now directly owns 35,586 shares in the company, valued at approximately $6,779,488.86. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Insulet news, Director Timothy J. Scannell sold 3,300 shares of the company's stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $180.90, for a total transaction of $596,970.00. Following the sale, the director now directly owns 42,586 shares of the company's stock, valued at $7,703,807.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Timothy J. Scannell sold 7,000 shares of the stock in a transaction on Monday, June 10th. The stock was sold at an average price of $190.51, for a total value of $1,333,570.00. Following the sale, the director now owns 35,586 shares in the company, valued at approximately $6,779,488.86. The disclosure for this sale can be found here. In the last 90 days, insiders sold 13,931 shares of company stock worth $2,636,286. 0.47% of the stock is currently owned by corporate insiders.
Insulet Company Profile
(Get Free Report)Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.
Recommended Stories
- Five stocks we like better than Insulet
- What is a Low P/E Ratio and What Does it Tell Investors?
- Joby Aviation Stock: The Case for Upside Just Got Stronger
- Market Cap Calculator: How to Calculate Market Cap
- Conviction Firms for Microsoft's Double-Digit Stock Upside
- How to Use Stock Screeners to Find Stocks
- 5 Aggressive Growth Stocks for Long-Term Investors
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
→ Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (From Paradigm Press) (Ad)
Should you invest $1,000 in Insulet right now?
Before you consider Insulet, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insulet wasn't on the list.
While Insulet currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
